Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial.

Study answer

What this study found

Daily n-3 PUFA supplementation did not reduce recurrent cardiovascular events or all-cause mortality in this elderly post-MI population. The primary composite MACE outcome was 21.4% versus 20.0% (HR 1.07, 95% CI 0.82 to 1.40; p=0.62), and all-cause mortality was 5.54% versus 5.50% (HR 1.01, 95% CI 0.60 to 1.71; p=0.97). Nonfatal myocardial infarction, stroke, heart failure hospitalization, and unscheduled revascularization were also not significantly different. New-onset atrial fibrillation was numerically higher with n-3 PUFA (7.2% vs 4.0%; HR 1.84, 95% CI 0.98 to 3.45; p=0.06), while major…

Study & population

Randomized controlled trial in elderly adults aged 70 to 82 years who had recently survived an acute myocardial infarction and were receiving guideline-directed secondary prevention.

Intervention

Oral Pikasol® n-3 PUFA capsules provided 1.8 g/day total marine omega-3, consisting of 930 mg EPA plus 660 mg DHA.

Key limitation

Event rates for several endpoints were modest, leaving wide confidence intervals around effect estimates.

View full study detailsView sourceOpen PDF

Original abstract